Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

Fase III, åpen etikett, studie av førstelinje Dato-DXd i kombinasjon med Rilvegostomig for avansert ikke-plateepitel NSCLC med høyt PD-L1-uttrykk (TC ≥ 50%) og uten handlingsbare genomiske endringer (TROPION-Lung10)

27. oktober 2026 oppdatert av: AstraZeneca

En fase III, randomisert, åpen, global studie av Datopotamab Deruxtecan (Dato-DXd) i kombinasjon med Rilvegostomig eller Rilvegostomig monoterapi versus Pembrolizumab monoterapi for førstelinjebehandling av deltakere med lokalt avansert eller metastatisk ikke-LC-squam PD-L1-uttrykk (TC ≥ 50%) og uten handlingsbare genomiske endringer (TROPION-Lung10)

The purpose of this study is to evaluate efficacy and safety of Dato-DXd in combination with rilvegostomig or rilvegostomig monotherapy compared with pembrolizumab monotherapy as a first line therapy in participants with locally advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Studieoversikt

Status

Rekruttering

Forhold

Intervensjon / Behandling

Detaljert beskrivelse

This is a Phase III, randomized, open-label, Global Study of Datopotamab Deruxtecan (Dato-DXd) in Combination With Rilvegostomig or Rilvegostomig monotherapy compared with Pembrolizumab monotherapy for the first-line treatment of participants with locally-advanced or metastatic non-squamous NSCLC with high PD-L1 expression (TC ≥ 50%) and without actionable genomic alterations.

Studietype

Intervensjonell

Registrering (Antatt)

675

Fase

  • Fase 3

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

      • Birtinya, Australia, 4575
        • Tilbaketrukket
        • Research Site
      • Blacktown, Australia, 2148
        • Tilbaketrukket
        • Research Site
      • Clayton, Australia, 3168
        • Rekruttering
        • Research Site
      • Gosford, Australia, 2250
        • Rekruttering
        • Research Site
      • Melbourne, Australia, 3000
        • Tilbaketrukket
        • Research Site
      • South Brisbane, Australia, QL 4101
        • Rekruttering
        • Research Site
      • Wodonga, Australia, 3690
        • Rekruttering
        • Research Site
      • Anderlecht, Belgia, 1070
        • Tilbaketrukket
        • Research Site
      • Bruges, Belgia, 8000
        • Rekruttering
        • Research Site
      • Hasselt, Belgia, 3500
        • Rekruttering
        • Research Site
      • La Louvière, Belgia, 7100
        • Rekruttering
        • Research Site
      • Liège, Belgia, 4000
        • Rekruttering
        • Research Site
      • Barretos, Brasil, 14784-400
        • Rekruttering
        • Research Site
      • Curitiba, Brasil, 80730-150
        • Rekruttering
        • Research Site
      • Florianópolis, Brasil, 88034-000
        • Rekruttering
        • Research Site
      • Ipatinga, Brasil, 35162-189
        • Rekruttering
        • Research Site
      • Natal, Brasil, 59075-740
        • Rekruttering
        • Research Site
      • Porto Alegre, Brasil, 91350-200
        • Rekruttering
        • Research Site
      • Rio de Janeiro, Brasil, 22211-230
        • Rekruttering
        • Research Site
      • Santa Maria, Brasil, 97015-450
        • Rekruttering
        • Research Site
      • São Paulo, Brasil, 01221-020
        • Rekruttering
        • Research Site
      • Taubaté, Brasil, 12030-200
        • Rekruttering
        • Research Site
      • Chicoutimi, Canada, G7H 5H6
        • Rekruttering
        • Research Site
    • British Columbia
      • Vancouver, British Columbia, Canada, VSZ 4E6
        • Rekruttering
        • Research Site
    • Manitoba
      • Winnipeg, Manitoba, Canada, R3E 0V9
        • Tilbaketrukket
        • Research Site
    • Newfoundland and Labrador
      • St. John's, Newfoundland and Labrador, Canada, A1B 3V6
        • Rekruttering
        • Research Site
    • Ontario
      • London, Ontario, Canada, N6A 4L6
        • Rekruttering
        • Research Site
      • Newmarket, Ontario, Canada, L3Y 2P9
        • Tilbaketrukket
        • Research Site
      • Oshawa, Ontario, Canada, L1G 2B9
        • Rekruttering
        • Research Site
      • Toronto, Ontario, Canada, M4N 3M5
        • Tilbaketrukket
        • Research Site
    • Quebec
      • Lévis, Quebec, Canada, G6V 0B8
        • Rekruttering
        • Research Site
      • Montreal, Quebec, Canada, H4J 1C5
        • Rekruttering
        • Research Site
      • Montreal, Quebec, Canada, H3T 1E2
        • Rekruttering
        • Research Site
      • Montreal, Quebec, Canada, H3T 1M5
        • Tilbaketrukket
        • Research Site
      • Rimouski, Quebec, Canada, G5L 5T1
        • Rekruttering
        • Research Site
      • Trois-Rivières, Quebec, Canada, G8Z 3R9
        • Rekruttering
        • Research Site
    • Saskatchewan
      • Saskatoon, Saskatchewan, Canada, S7N 4H4
        • Rekruttering
        • Research Site
    • Alaska
      • Anchorage, Alaska, Forente stater, 99508
        • Rekruttering
        • Research Site
    • Arizona
      • Tucson, Arizona, Forente stater, 85719
        • Rekruttering
        • Research Site
    • Arkansas
      • Little Rock, Arkansas, Forente stater, 72205
        • Rekruttering
        • Research Site
      • Springdale, Arkansas, Forente stater, 72762
        • Rekruttering
        • Research Site
    • California
      • Anaheim, California, Forente stater, 92801
        • Rekruttering
        • Research Site
      • Beverly Hills, California, Forente stater, 90211
        • Rekruttering
        • Research Site
      • Fountain Valley, California, Forente stater, 92708
        • Rekruttering
        • Research Site
      • Newport Beach, California, Forente stater, 92663
        • Suspendert
        • Research Site
    • Florida
      • Clermont, Florida, Forente stater, 34711
        • Rekruttering
        • Research Site
      • Gainesville, Florida, Forente stater, 32608
        • Rekruttering
        • Research Site
      • Miami Beach, Florida, Forente stater, 33140
        • Rekruttering
        • Research Site
      • Orange City, Florida, Forente stater, 32763
        • Rekruttering
        • Research Site
      • Orlando, Florida, Forente stater, 32806
        • Rekruttering
        • Research Site
      • Orlando, Florida, Forente stater, 32827
        • Tilbaketrukket
        • Research Site
      • West Palm Beach, Florida, Forente stater, 33401
        • Rekruttering
        • Research Site
    • Georgia
      • Atlanta, Georgia, Forente stater, 30322
        • Rekruttering
        • Research Site
      • Atlanta, Georgia, Forente stater, 30318
        • Rekruttering
        • Research Site
      • Atlanta, Georgia, Forente stater, 30342
        • Tilbaketrukket
        • Research Site
      • Atlanta, Georgia, Forente stater, 30303
        • Suspendert
        • Research Site
    • Illinois
      • Hinsdale, Illinois, Forente stater, 60521
        • Rekruttering
        • Research Site
    • Indiana
      • Noblesville, Indiana, Forente stater, 46062
        • Rekruttering
        • Research Site
    • Kentucky
      • Paducah, Kentucky, Forente stater, 42003
        • Rekruttering
        • Research Site
    • Maryland
      • Annapolis, Maryland, Forente stater, 21401
        • Rekruttering
        • Research Site
    • Massachusetts
      • Boston, Massachusetts, Forente stater, 02215
        • Rekruttering
        • Research Site
      • Boston, Massachusetts, Forente stater, 02114
        • Rekruttering
        • Research Site
    • Michigan
      • Dearborn, Michigan, Forente stater, 48126
        • Rekruttering
        • Research Site
      • Farmington Hills, Michigan, Forente stater, 48334
        • Rekruttering
        • Research Site
      • Grand Rapids, Michigan, Forente stater, 49503
        • Rekruttering
        • Research Site
      • Traverse City, Michigan, Forente stater, 49684
        • Tilbaketrukket
        • Research Site
    • Mississippi
      • Hattiesburg, Mississippi, Forente stater, 39401
        • Rekruttering
        • Research Site
    • Missouri
      • Kansas City, Missouri, Forente stater, 64132
        • Rekruttering
        • Research Site
    • Montana
      • Bozeman, Montana, Forente stater, 59715
        • Tilbaketrukket
        • Research Site
    • Nebraska
      • Grand Island, Nebraska, Forente stater, 68803
        • Rekruttering
        • Research Site
      • Omaha, Nebraska, Forente stater, 68130
        • Rekruttering
        • Research Site
    • Nevada
      • Las Vegas, Nevada, Forente stater, 89102
        • Rekruttering
        • Research Site
      • Reno, Nevada, Forente stater, 89502
        • Tilbaketrukket
        • Research Site
    • New Jersey
      • Voorhees Township, New Jersey, Forente stater, 08043
        • Suspendert
        • Research Site
    • New York
      • Stony Brook, New York, Forente stater, 11794
        • Rekruttering
        • Research Site
    • North Carolina
      • Greenville, North Carolina, Forente stater, 27834
        • Rekruttering
        • Research Site
      • Salisbury, North Carolina, Forente stater, 28144
        • Rekruttering
        • Research Site
    • Ohio
      • Cincinnati, Ohio, Forente stater, 45219
        • Rekruttering
        • Research Site
      • Columbus, Ohio, Forente stater, 43210
        • Tilbaketrukket
        • Research Site
      • Maumee, Ohio, Forente stater, 43537
        • Rekruttering
        • Research Site
      • Toledo, Ohio, Forente stater, 43623
        • Rekruttering
        • Research Site
    • Oregon
      • Portland, Oregon, Forente stater, 97213
        • Tilbaketrukket
        • Research Site
    • South Carolina
      • Greenville, South Carolina, Forente stater, 29607
        • Rekruttering
        • Research Site
    • South Dakota
      • Sioux Falls, South Dakota, Forente stater, 57105
        • Rekruttering
        • Research Site
    • Tennessee
      • Chattanooga, Tennessee, Forente stater, 37404
        • Tilbaketrukket
        • Research Site
      • Knoxville, Tennessee, Forente stater, 37920
        • Tilbaketrukket
        • Research Site
    • Texas
      • Fort Worth, Texas, Forente stater, 76104
        • Rekruttering
        • Research Site
      • Houston, Texas, Forente stater, 77030
        • Rekruttering
        • Research Site
      • Houston, Texas, Forente stater, 77030
        • Tilbaketrukket
        • Research Site
      • Houston, Texas, Forente stater, 77090
        • Suspendert
        • Research Site
      • Kingwood, Texas, Forente stater, 77339
        • Rekruttering
        • Research Site
      • Odessa, Texas, Forente stater, 79761
        • Rekruttering
        • Research Site
    • Virginia
      • Fort Belvoir, Virginia, Forente stater, 22060
        • Rekruttering
        • Research Site
      • Leesburg, Virginia, Forente stater, 20176
        • Rekruttering
        • Research Site
      • Midlothian, Virginia, Forente stater, 23114
        • Rekruttering
        • Research Site
      • Richmond, Virginia, Forente stater, 23230
        • Rekruttering
        • Research Site
    • Washington
      • Tacoma, Washington, Forente stater, 98405
        • Rekruttering
        • Research Site
      • Vancouver, Washington, Forente stater, 98684
        • Rekruttering
        • Research Site
      • Wenatchee, Washington, Forente stater, 98801
        • Rekruttering
        • Research Site
    • Wisconsin
      • Appleton, Wisconsin, Forente stater, 54911
        • Rekruttering
        • Research Site
      • Chennai, India, 600031
        • Rekruttering
        • Research Site
      • Dwārka, India, 110075
        • Rekruttering
        • Research Site
      • Jaipur, India, 302004
        • Rekruttering
        • Research Site
      • Kolkata, India, 700099
        • Rekruttering
        • Research Site
      • Marg Jaipur, India, 302004
        • Tilbaketrukket
        • Research Site
      • Nagpur, India, 440001
        • Rekruttering
        • Research Site
      • Nashik, India, 422011
        • Rekruttering
        • Research Site
      • New Delhi, India, 11029
        • Rekruttering
        • Research Site
      • New Delhi, India, 110085
        • Rekruttering
        • Research Site
      • Surat, India, 395002
        • Rekruttering
        • Research Site
      • Thiruvananthapuram, India, 695011
        • Tilbaketrukket
        • Research Site
      • Bergamo, Italia, 24125
        • Rekruttering
        • Research Site
      • Genoa, Italia, 16132
        • Rekruttering
        • Research Site
      • Milan, Italia, 20141
        • Rekruttering
        • Research Site
      • Milan, Italia, 20162
        • Rekruttering
        • Research Site
      • Monza, Italia, 20052
        • Rekruttering
        • Research Site
      • Padova, Italia, 35128
        • Rekruttering
        • Research Site
      • Pavia, Italia, 27100
        • Rekruttering
        • Research Site
      • Ravenna, Italia, 48100
        • Rekruttering
        • Research Site
      • Roma, Italia, 00128
        • Rekruttering
        • Research Site
      • Rozzano, Italia, 20089
        • Rekruttering
        • Research Site
      • Bunkyō City, Japan, 113-8431
        • Rekruttering
        • Research Site
      • Bunkyō City, Japan, 160-0023
        • Rekruttering
        • Research Site
      • Fukuoka, Japan, 812-8582
        • Rekruttering
        • Research Site
      • Fukuoka, Japan, 814-0180
        • Rekruttering
        • Research Site
      • Hakodate-shi, Japan, 040-8611
        • Rekruttering
        • Research Site
      • Hidaka-shi, Japan, 350-1298
        • Rekruttering
        • Research Site
      • Hirakata-shi, Japan, 573-1191
        • Rekruttering
        • Research Site
      • Hirosaki-shi, Japan, 036-8563
        • Rekruttering
        • Research Site
      • Hiroshima, Japan, 730-8518
        • Rekruttering
        • Research Site
      • Kanazawa, Japan, 920-8641
        • Rekruttering
        • Research Site
      • Kashiwa, Japan, 227-8577
        • Rekruttering
        • Research Site
      • Kawasaki-shi, Japan, 216-8511
        • Rekruttering
        • Research Site
      • Kumamoto, Japan, 860-8556
        • Rekruttering
        • Research Site
      • Matsusaka-shi, Japan, 515-8544
        • Rekruttering
        • Research Site
      • Matsuyama, Japan, 790-0024
        • Rekruttering
        • Research Site
      • Nagoya, Japan, 460-0001
        • Rekruttering
        • Research Site
      • Niigata, Japan, 951-8566
        • Rekruttering
        • Research Site
      • Okayama, Japan, 700-8558
        • Rekruttering
        • Research Site
      • Osaka, Japan, 545-8586
        • Tilbaketrukket
        • Research Site
      • Osakasayama-shi, Japan, 589-8511
        • Rekruttering
        • Research Site
      • Sagamihara-shi, Japan, 252-0375
        • Rekruttering
        • Research Site
      • Sapporo, Japan, 003-0804
        • Rekruttering
        • Research Site
      • Takaoka-shi, Japan, 933-8555
        • Rekruttering
        • Research Site
      • Takatsuki-shi, Japan, 569-8686
        • Rekruttering
        • Research Site
      • Tokushima, Japan, 770-8503
        • Rekruttering
        • Research Site
      • Tokyo, Japan, 104-0045
        • Rekruttering
        • Research Site
      • Utsunomiya, Japan, 320-0834
        • Rekruttering
        • Research Site
      • Yokohama, Japan, 221-0855
        • Rekruttering
        • Research Site
      • Beijing, Kina, 100142
        • Rekruttering
        • Research Site
      • Beijing, Kina, 101149
        • Rekruttering
        • Research Site
      • Changchun, Kina, 130000
        • Rekruttering
        • Research Site
      • Changsha, Kina, 410013
        • Rekruttering
        • Research Site
      • Chengdu, Kina, 610000
        • Rekruttering
        • Research Site
      • Chengdu, Kina, 610041
        • Rekruttering
        • Research Site
      • Chongqing, Kina, 400030
        • Rekruttering
        • Research Site
      • Fuzhou, Kina, 350014
        • Rekruttering
        • Research Site
      • Guangzhou, Kina, 510080
        • Rekruttering
        • Research Site
      • Hangzhou, Kina, 310006
        • Rekruttering
        • Research Site
      • Hangzhou, Kina, 310022
        • Rekruttering
        • Research Site
      • Hangzhou, Kina, 310016
        • Rekruttering
        • Research Site
      • Harbin, Kina, 150049
        • Rekruttering
        • Research Site
      • Hefei, Kina, 230601
        • Rekruttering
        • Research Site
      • Hefei, Kina, 230031
        • Tilbaketrukket
        • Research Site
      • Jinan, Kina, 250117
        • Rekruttering
        • Research Site
      • Jining, Kina, 272011
        • Tilbaketrukket
        • Research Site
      • Kunming, Kina, 650118
        • Rekruttering
        • Research Site
      • Lanzhou, Kina, 730000
        • Rekruttering
        • Research Site
      • Linhai, Kina, 317000
        • Rekruttering
        • Research Site
      • Linyi, Kina, 276001
        • Rekruttering
        • Research Site
      • Nanjing, Kina, 210009
        • Rekruttering
        • Research Site
      • Nanning, Kina, 530021
        • Rekruttering
        • Research Site
      • Nanning, Kina, 530000
        • Rekruttering
        • Research Site
      • Shanghai, Kina, 200032
        • Rekruttering
        • Research Site
      • Shanghai, Kina, 200030
        • Rekruttering
        • Research Site
      • Shanghai, Kina, 200433
        • Rekruttering
        • Research Site
      • Shenyang, Kina, 110022
        • Rekruttering
        • Research Site
      • Taiyuan, Kina, 030000
        • Rekruttering
        • Research Site
      • Tianjin, Kina, 300060
        • Rekruttering
        • Research Site
      • Wenzhou, Kina, 325000
        • Rekruttering
        • Research Site
      • Wuhan, Kina, 430022
        • Rekruttering
        • Research Site
      • Wuhan, Kina, 430030
        • Rekruttering
        • Research Site
      • Wuhan, Kina, 430010
        • Rekruttering
        • Research Site
      • Wuhan, Kina, 430000
        • Rekruttering
        • Research Site
      • Xi'an, Kina, 710061
        • Rekruttering
        • Research Site
      • Yangzhou, Kina, 225001
        • Rekruttering
        • Research Site
      • Zhengzhou, Kina, 450000
        • Rekruttering
        • Research Site
      • Zhengzhou, Kina, 450008
        • Rekruttering
        • Research Site
      • Olsztyn, Polen, 10-357
        • Rekruttering
        • Research Site
      • Poznan, Polen, 60-569
        • Rekruttering
        • Research Site
      • Przemyśl, Polen, 37-700
        • Rekruttering
        • Research Site
      • Warsaw, Polen, 02-781
        • Rekruttering
        • Research Site
      • Warsaw, Polen, 01-138
        • Rekruttering
        • Research Site
      • San Juan, Puerto Rico, 00909
        • Rekruttering
        • Research Site
      • Alicante, Spania, 03010
        • Rekruttering
        • Research Site
      • Barcelona, Spania, 08036
        • Rekruttering
        • Research Site
      • Barcelona, Spania, 08003
        • Rekruttering
        • Research Site
      • Barcelona, Spania, 08041
        • Har ikke rekruttert ennå
        • Research Site
      • Jerez de la Frontera, Spania, 11407
        • Rekruttering
        • Research Site
      • Reus, Spania, 43204
        • Rekruttering
        • Research Site
      • Salamanca, Spania, 37007
        • Tilbaketrukket
        • Research Site
      • Cheltenham, Storbritannia, GL53 7AN
        • Suspendert
        • Research Site
      • Inverness, Storbritannia, IV2 3UJ
        • Suspendert
        • Research Site
      • London, Storbritannia, SW17 0QT
        • Rekruttering
        • Research Site
      • London, Storbritannia, SW10 9NH
        • Rekruttering
        • Research Site
      • London, Storbritannia, SE1 9RT
        • Tilbaketrukket
        • Research Site
      • Norwich, Storbritannia, NR4 7UY
        • Rekruttering
        • Research Site
      • Preston, Storbritannia, PR2 9HT
        • Rekruttering
        • Research Site
      • Truro, Storbritannia, TR1 3LJ
        • Rekruttering
        • Research Site
      • Changwon, Sør -Korea, 51353
        • Rekruttering
        • Research Site
      • Incheon, Sør -Korea, 21565
        • Rekruttering
        • Research Site
      • Seongnam-si, Sør -Korea, 13496
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 03080
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 03722
        • Rekruttering
        • Research Site
      • Seoul, Sør -Korea, 08308
        • Har ikke rekruttert ennå
        • Research Site
      • Seoul, Sør -Korea, 06973
        • Rekruttering
        • Research Site
      • Suwon, Sør -Korea, 16247
        • Rekruttering
        • Research Site
      • Suwon, Sør -Korea, 16499
        • Rekruttering
        • Research Site
      • Changhua, Taiwan, 500
        • Har ikke rekruttert ennå
        • Research Site
      • Kaohsiung City, Taiwan, 80756
        • Rekruttering
        • Research Site
      • New Taipei City, Taiwan, 220
        • Rekruttering
        • Research Site
      • Taichung, Taiwan, 40447
        • Rekruttering
        • Research Site
      • Taichung, Taiwan, 40705
        • Rekruttering
        • Research Site
      • Tainan, Taiwan, 704
        • Rekruttering
        • Research Site
      • Taipei, Taiwan, TAIWAN
        • Rekruttering
        • Research Site
      • Taipei, Taiwan, 10002
        • Rekruttering
        • Research Site
      • Taipei, Taiwan, 112
        • Rekruttering
        • Research Site
      • Taipei, Taiwan, 0116
        • Rekruttering
        • Research Site
      • Taoyuan, Taiwan, 333
        • Rekruttering
        • Research Site
      • Bangkok, Thailand, 10400
        • Rekruttering
        • Research Site
      • Bangkok, Thailand, 10700
        • Rekruttering
        • Research Site
      • Hat Yai, Thailand, 90110
        • Rekruttering
        • Research Site
      • Muang, Thailand, 22000
        • Rekruttering
        • Research Site
      • Mueang, Thailand, 20000
        • Rekruttering
        • Research Site
      • Mueang, Thailand, 32000
        • Rekruttering
        • Research Site
      • Adapazarı, Tyrkia (Türkiye), 54100
        • Rekruttering
        • Research Site
      • Ankara, Tyrkia (Türkiye), 6200
        • Rekruttering
        • Research Site
      • Ankara, Tyrkia (Türkiye), 06560
        • Rekruttering
        • Research Site
      • Antalya, Tyrkia (Türkiye), 07070
        • Rekruttering
        • Research Site
      • Diyarbakır, Tyrkia (Türkiye), 21280
        • Rekruttering
        • Research Site
      • Istanbul, Tyrkia (Türkiye), 34030
        • Rekruttering
        • Research Site
      • Istanbul, Tyrkia (Türkiye), 34890
        • Rekruttering
        • Research Site
      • Berlin, Tyskland, 10249
        • Har ikke rekruttert ennå
        • Research Site
      • Bonn, Tyskland, 53113
        • Rekruttering
        • Research Site
      • Cologne, Tyskland, 50677
        • Rekruttering
        • Research Site
      • Düsseldorf, Tyskland, 40489
        • Tilbaketrukket
        • Research Site
      • Essen, Tyskland, 45136
        • Rekruttering
        • Research Site
      • Freiburg im Breisgau, Tyskland, 79106
        • Rekruttering
        • Research Site
      • Gauting, Tyskland, 82131
        • Rekruttering
        • Research Site
      • Georgsmarienhütte, Tyskland, 49124
        • Tilbaketrukket
        • Research Site
      • Gera, Tyskland, 07548
        • Tilbaketrukket
        • Research Site
      • Gütersloh, Tyskland, 33332
        • Tilbaketrukket
        • Research Site
      • Hamburg, Tyskland, 20251
        • Rekruttering
        • Research Site
      • Hamburg, Tyskland, 22087
        • Rekruttering
        • Research Site
      • Heidelberg, Tyskland, 69126
        • Rekruttering
        • Research Site
      • Kempten, Tyskland, 87439
        • Suspendert
        • Research Site
      • Kiel, Tyskland, 24116
        • Har ikke rekruttert ennå
        • Research Site
      • Koblenz, Tyskland, 56068
        • Suspendert
        • Research Site
      • Ludwigsburg, Tyskland, 71640
        • Tilbaketrukket
        • Research Site
      • München, Tyskland, 81925
        • Rekruttering
        • Research Site
      • Nuremberg, Tyskland, 90419
        • Tilbaketrukket
        • Research Site
      • Potsdam, Tyskland, 14467
        • Rekruttering
        • Research Site
      • Ravensburg, Tyskland, 88212
        • Rekruttering
        • Research Site
      • Budapest, Ungarn, 1121
        • Rekruttering
        • Research Site
      • Edelény, Ungarn, 3780
        • Har ikke rekruttert ennå
        • Research Site
      • Gyula, Ungarn, 5700
        • Suspendert
        • Research Site
      • Gyöngyös, Ungarn, 3200
        • Tilbaketrukket
        • Research Site
      • Gyöngyös - Mátraháza, Ungarn, 3200
        • Rekruttering
        • Research Site
      • Győr, Ungarn, 9024
        • Rekruttering
        • Research Site
      • Kecskemét, Ungarn, 6000
        • Rekruttering
        • Research Site
      • Salgótarján, Ungarn, 3100
        • Tilbaketrukket
        • Research Site
      • Szekszárd, Ungarn, 7100
        • Rekruttering
        • Research Site
      • Szolnok, Ungarn, 5000
        • Tilbaketrukket
        • Research Site
      • Székesfehérvár, Ungarn, 8000
        • Tilbaketrukket
        • Research Site
      • Törökbálint, Ungarn, 2045
        • Rekruttering
        • Research Site
      • Da Nang, Vietnam, 550000
        • Rekruttering
        • Research Site
      • Hanoi, Vietnam, 100000
        • Rekruttering
        • Research Site
      • Ho Chi Minh City, Vietnam, 700000
        • Rekruttering
        • Research Site
      • Ho Chi Minh City, Vietnam, 700000
        • Tilbaketrukket
        • Research Site
      • Huế, Vietnam, 530000
        • Tilbaketrukket
        • Research Site
      • Hà Nội, Vietnam, 100000
        • Rekruttering
        • Research Site
      • Vinh, Vietnam, 460000
        • Tilbaketrukket
        • Research Site
      • Vĩnh Yên, Vietnam, 280000
        • Rekruttering
        • Research Site
      • Innsbruck, Østerrike, 6020
        • Rekruttering
        • Research Site
      • Krems, Østerrike, 3500
        • Rekruttering
        • Research Site
      • Linz, Østerrike, 4020
        • Rekruttering
        • Research Site
      • Rankweil, Østerrike, 6830
        • Rekruttering
        • Research Site
      • Vienna, Østerrike, 1210
        • Rekruttering
        • Research Site
      • Vienna, Østerrike, 1140
        • Rekruttering
        • Research Site
      • Wels, Østerrike, 4600
        • Tilbaketrukket
        • Research Site

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

18 år og eldre (Voksen, Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Histologically or cytologically documented non-squamous NSCLC.
  • Stage IIIB or IIIC or Stage IV metastatic NSCLC (according to Edition 8 of the AJCC staging manual) not amenable to curative surgery or definitive chemoradiation.
  • Absence of sensitising EGFR mutations, and ALK and ROS1 rearrangements, and absence of documented local test result for any other known genomic alteration for which there are locally approved and available targeted first-line therapies.
  • Must provide tumor sample to determine PD-L1 status, TROP2 status and other biomarkers.
  • Known tumour PD-L1 expression status defined as TC ≥ 50%
  • At least one lesion, not previously irradiated that qualifies as a RECIST 1.1 target lesion at baseline
  • ECOG performance status of 0 or 1
  • Adequate bone marrow reserve and organ function

Exclusion Criteria:

  • Prior systemic therapy for advanced/metastatic NSCLC.
  • Squamous cell histology, or predominantly squamous cell histology NSCLC; mixed small cell lung cancer; NSCLC histology, sarcomatoid variant.
  • History of another primary malignancy within 3 years
  • Active or prior documented autoimmune or inflammatory disorders (with exceptions)
  • Any evidence of severe or uncontrolled disease that makes it undesirable for the participant to participate in the study or that would jeopardies compliance with the protocol.
  • Has clinically significant third-space fluid retention (for example pleural effusion) and is not amenable for repeated drainage.
  • History of any ILD/pneumonitis, including radiation pneumonitis (apart from radiation pneumonitis that did not require steroids), or drug-induced ILD/pneumonitis, has current or suspected ILD/pneumonitis that cannot be ruled out by imaging at screening.
  • Has significant pulmonary function compromise, as determined by the investigator
  • Spinal cord compression, or brain metastases unless participant treated and no longer symptomatic, radiologically stable, and who require no treatment with corticosteroids or anticonvulsants.
  • History of leptomeningeal carcinomatosis
  • Known clinically significant corneal disease
  • Active infection with TB, HBV, HCV, Hepatitis A, or known HIV infection that is not well controlled
  • History of active primary immunodeficiency

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Enkelt

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Eksperimentell: Arm 1: Datopotamab Deruxtecan in Combination With Rilvegostomig

Participants in the Datopotamab Deruxtecan (Dato-DXd) in combination with Rilvegostomig group will receive Dato-DXd plus rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Datopotamab Deruxtecan IV (intravenous)

Andre navn:
  • Dato-DXd

Rilvegostomig IV (intravenous)

Andre navn:
  • AZD2936
Eksperimentell: Arm 2: Rilvegostomig Monotherapy

Participants in the rilvegostomig monotherapy group will receive rilvegostomig as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Rilvegostomig IV (intravenous)

Andre navn:
  • AZD2936
Aktiv komparator: Arm 3: Pembrolizumab Monotherapy

Participants in the pembrolizumab group will receive pembrolizumab as intravenous (IV) infusion every 3 weeks (Q3W) on Day 1 of each 21-day cycle.

Pembrolizumab IV (intravenous)

Andre navn:
  • KEYTRUDA

Hva måler studien?

Primære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-Free Survival (PFS) in TROP2 biomarker positive participants.
Tidsramme: Approximately 4 years

PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti-cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population:

• TROP2 biomarker positive population

The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis.

Approximately 4 years
Overall Survival (OS) in TROP2 biomarker positive participants.
Tidsramme: Approximately 6 years

OS is defined as the time from randomisation until the date of death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population:

• TROP2 biomarker positive population The measure of interest is the HR of OS.

Approximately 6 years

Sekundære resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Progression-Free Survival (PFS) in the FAS population.
Tidsramme: Approximately 4 years

PFS is defined as time from randomisation until progression per RECIST 1.1 as assessed by BICR, or death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following population:

• FAS population

The measure of interest is the HR of PFS. PFS by investigator will be reported as a sensitivity analysis.

Approximately 4 years
Overall Survival (OS) in the FAS population.
Tidsramme: Approximately 6 years

OS is defined as the time from randomisation until the date of death due to any cause.

The analysis will include all randomised participants, as randomised, regardless of whether the participant withdraws from randomised therapy or receives another anti-cancer therapy, in the following population:

• FAS population The measure of interest is the HR of OS.

Approximately 6 years
Assessment of Objective Response Rate (ORR) by BICR in TROP2 biomarker positive and FAS populations
Tidsramme: Approximately 4 years

ORR is defined as the proportion of participants who have a CR or PR, as determined by BICR per RECIST 1.1.

The analyses will include all randomised participants, as randomised, with measurable disease at baseline, in the following populations:

  • TROP2 biomarker positive population
  • FAS population Data obtained from randomisation up until progression, or the last evaluable assessment in the absence of progression, will be included in the assessment of ORR, regardless of whether the participant withdraws from therapy. Participants who go off treatment without a response or progression, receive a subsequent therapy, and then respond will not be included as responders in the ORR.

The measure of interest is the difference of the ORR. ORR by investigator will be reported as a sensitivity analysis.

Approximately 4 years
Assessment of Duration of Response (DoR) by BICR in TROP2 biomarker positive and FAS populations
Tidsramme: Approximately 4 years

DoR is defined as the time from the date of first documented response until date of documented progression per RECIST 1.1, as assessed by BICR or death due to any cause.

The analyses will include all randomised participants who have a response, as randomised, regardless of whether the participant withdraws from randomised therapy, receives another anti cancer therapy or clinically progresses prior to RECIST 1.1 progression, in the following populations:

  • TROP2 biomarker positive population
  • FAS population The measure of interest is the median of DoR. DoR by investigator will be reported as a sensitivity analysis.
Approximately 4 years
Participant-reported lung cancer symptoms of NSCLC and participant-reported GHS/QOL in participants treated with Dato-DXd in combination with rilvegostomig relative to pembrolizumab.
Tidsramme: Approximately 6 years

Time to deterioration in: pulmonary symptoms (dyspnoea, cough, and chest pain) as measured by the NSCLC-SAQ, in overall lung cancer symptoms as measured by the NSCLC-SAQ, and in GHS/QoL as measured by the GHS/QoL scale from EORTC IL172.

Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:

  • TROP2 biomarker positive population
  • FAS population The measure of interest is the HR of time to deterioration in pulmonary symptoms, HR of time to deterioration in overall lung cancer symptoms, and HR of time to deterioration in GHS/QoL.
Approximately 6 years
Participant-reported physical functioning in participants treated with Dato DXd in combination with rilvegostomig relative to pembrolizumab.
Tidsramme: Approximately 6 years

Time to deterioration in physical functioning as measured by PROMIS Physical Function short form 8c.

Time to deterioration is defined as the time from randomisation until the date of deterioration. Deterioration is defined as change from baseline that reaches a clinically meaningful deterioration threshold. The analyses will include all randomised participants, in the following populations:

  • TROP2 biomarker positive population
  • FAS population The measure of interest is the HR of time to deterioration in physical functioning.
Approximately 6 years
Pharmacokinetics (PK)
Tidsramme: Approximately 6 years

Concentration of rilvegostomig, Dato-DXd, total anti TROP2 antibody, and MAAA 1181a (payload deruxtecan) in plasma or serum and PK parameters (peak and trough concentrations).

Approximately 6 years
Immunogenicity
Tidsramme: Approximately 6 years

Presence of ADA for Dato-DXd and rilvegostomig (confirmatory results, titres and neutralising antibodies for confirmed positive samples).

Approximately 6 years
Second Progression-Free Survival (PFS2).
Tidsramme: Approximately 6 years

PFS2 is defined as the time from randomisation to the earliest of the progression events (following the initial progression), subsequent to first subsequent therapy, or death. Progression event includes radiological (RECIST 1.1) or clinical disease progression.

The date of second progression will be recorded by the investigator in the eCRF and defined according to local standard practice.

The analyses will include all randomised participants, as randomised, regardless of whether the participant withdraws from subsequent therapy and regardless of missed visits, in the following populations:

  • TROP2 biomarker positive population
  • FAS population The measure of interest is the HR of PFS2.
Approximately 6 years

Andre resultatmål

Resultatmål
Tiltaksbeskrivelse
Tidsramme
Safety of Dato-DXd in combination with rilvegostomig and rilvegostomig monotherapy as compared with pembrolizumab.
Tidsramme: Approximately 6 years

Safety and tolerability will be evaluated in terms of AEs (graded by CTCAE Version 5.0).

Approximately 6 years

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Sponsor

Samarbeidspartnere

Etterforskere

  • Hovedetterforsker: Suresh S. Ramalingam, MD, Emory University, Atlanta, Georgia, United States of America.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

11. april 2024

Primær fullføring (Antatt)

28. desember 2029

Studiet fullført (Antatt)

28. desember 2029

Datoer for studieregistrering

Først innsendt

5. april 2024

Først innsendt som oppfylte QC-kriteriene

5. april 2024

Først lagt ut (Faktiske)

10. april 2024

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

28. oktober 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

27. oktober 2026

Sist bekreftet

1. oktober 2026

Mer informasjon

Begreper knyttet til denne studien

Andre studie-ID-numre

  • D7632C00001
  • 2023-505077-32-00 (Registeridentifikator: CTIS (EU))
  • 2023 (U.S. NIH-stipend/kontrakt)

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

JA

IPD-planbeskrivelse

Qualified researchers can request access to anonymized individual patient-level data from AstraZeneca group of companies sponsored clinical trials via the request portal.

All request will be evaluated as per the AZ disclosure commitment: https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

IPD-delingstidsramme

AstraZeneca will meet or exceed data availability as per the commitments made to the EFPIA Pharma Data Sharing Principles.

For details of our timelines, please rerefer to our disclosure commitment at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure

Tilgangskriterier for IPD-deling

When a request has been approved AstraZeneca will provide access to the deidentified individual patient-level data in an approved sponsored tool .

Signed Data Sharing Agreement (non-negotiable contract for data accessors) must be in place before accessing requested information.

Additionally, all users will need to accept the terms and conditions of the SAS MSE to gain access. For additional details, please review the Disclosure Statements at https://astrazenecagrouptrials.pharmacm.com/ST/Submission/Disclosure.

IPD-deling Støtteinformasjonstype

  • STUDY_PROTOCOL
  • SEVJE

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Ja

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .